JP2013530952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530952A5 JP2013530952A5 JP2013512793A JP2013512793A JP2013530952A5 JP 2013530952 A5 JP2013530952 A5 JP 2013530952A5 JP 2013512793 A JP2013512793 A JP 2013512793A JP 2013512793 A JP2013512793 A JP 2013512793A JP 2013530952 A5 JP2013530952 A5 JP 2013530952A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dissolution
- pharmaceutically acceptable
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 239000000654 additive Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims 14
- 239000013078 crystal Substances 0.000 claims 8
- 229960000590 celecoxib Drugs 0.000 claims 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 7
- 229960004380 tramadol Drugs 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 5
- 238000004090 dissolution Methods 0.000 claims 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 4
- 229920001531 copovidone Polymers 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229920002554 vinyl polymer Polymers 0.000 claims 4
- -1 acetate-polyethylene Chemical group 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical group CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 238000007907 direct compression Methods 0.000 claims 2
- 125000005456 glyceride group Chemical group 0.000 claims 2
- 229920000578 graft copolymer Polymers 0.000 claims 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 229940071138 stearyl fumarate Drugs 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010034464 Periarthritis Diseases 0.000 claims 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 201000010603 frozen shoulder Diseases 0.000 claims 1
- 229910021485 fumed silica Inorganic materials 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960000540 polacrilin potassium Drugs 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000009490 roller compaction Methods 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10384002A EP2392319A1 (en) | 2010-06-04 | 2010-06-04 | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
| EP10384002.1 | 2010-06-04 | ||
| PCT/EP2011/002749 WO2011151080A1 (en) | 2010-06-04 | 2011-06-03 | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530952A JP2013530952A (ja) | 2013-08-01 |
| JP2013530952A5 true JP2013530952A5 (enExample) | 2015-02-19 |
| JP5800016B2 JP5800016B2 (ja) | 2015-10-28 |
Family
ID=42358396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512793A Active JP5800016B2 (ja) | 2010-06-04 | 2011-06-03 | トラマドールとコキシブとの共結晶の医薬品組成物 |
Country Status (34)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
| EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| US9138425B2 (en) | 2013-03-12 | 2015-09-22 | Patheon Inc. | Drug delivery system to increase bioavailability |
| US20180104197A9 (en) | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
| US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
| AU2015254875A1 (en) | 2014-05-01 | 2016-11-17 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
| AU2015254874A1 (en) * | 2014-05-01 | 2016-11-17 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
| US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
| MA40448A (fr) | 2014-07-30 | 2016-02-04 | Sun Pharmaceutical Ind Ltd | Emballage à double chambre |
| WO2016046693A1 (en) * | 2014-09-25 | 2016-03-31 | Nathwani Sandeep Vinodkumar | A co-processed pharmaceutical excipient |
| CN104276960B (zh) * | 2014-09-26 | 2016-09-28 | 安徽省逸欣铭医药科技有限公司 | 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法 |
| US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
| US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
| WO2018031577A1 (en) * | 2016-08-09 | 2018-02-15 | Autotelic Llc | Fixed dose combination for pain relief without edema |
| DE102016012746A1 (de) | 2016-10-25 | 2018-04-26 | WindplusSonne GmbH | Vorprodukte zur Herstellung von porösen, mineralischen Leichtbaumaterialien, Verfahren zur Herstellung von porösen, mineralischen Leichtbaumaterialien und ihre Verwendung |
| WO2018111991A1 (en) * | 2016-12-14 | 2018-06-21 | Druggability Technologies Ip Holdco Limited | Pharmaceutical composition containing celecoxib |
| CN107595792A (zh) * | 2017-11-06 | 2018-01-19 | 刘丽 | 一种盐酸他喷他多塞来昔布片剂及其制备方法 |
| CN110101673A (zh) * | 2019-05-07 | 2019-08-09 | 安徽金太阳生化药业有限公司 | 一种盐酸曲马多分散片的制备方法 |
| PT3968978T (pt) * | 2019-05-14 | 2025-09-08 | Esteve Pharmaceuticals Sa | Cocristal de (rac) tramadol e celecoxibe para utilização no tratamento da dor em pacientes com dependência de tramadol |
| CN112007024A (zh) * | 2019-05-28 | 2020-12-01 | 江苏恒瑞医药股份有限公司 | 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途 |
| CN115251264B (zh) * | 2022-08-05 | 2023-11-21 | 齐鲁工业大学 | 含桑叶提取物的共结晶粉末功能性饮料及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1349423A (zh) * | 1999-03-01 | 2002-05-15 | 奥索-麦克尼尔药品公司 | 包含曲马多物质和选择性cox－2抑制剂药物的组合物 |
| DE10014588A1 (de) * | 2000-03-27 | 2001-10-04 | Basf Ag | Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| US20050090517A1 (en) * | 2002-02-19 | 2005-04-28 | Norris Michael C. | Pharmaceutical combinations of cox-2 inhibitors and opiates |
| JP2005154334A (ja) * | 2003-11-25 | 2005-06-16 | Toa Yakuhin Kk | アズレンスルホン酸塩水溶液剤 |
| DE102006044694A1 (de) * | 2006-09-22 | 2008-03-27 | Krewel Meuselbach Gmbh | Perorale feste Schmerzmittelzubereitung |
| WO2008085674A1 (en) * | 2007-01-04 | 2008-07-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions comprising celecoxib co-crystals |
| CN101254180B (zh) * | 2008-03-28 | 2010-11-10 | 辽宁正鑫药物研究有限公司 | 一种内容物为半固体组合物的尼莫地平胶囊剂及制备方法 |
| EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
-
2010
- 2010-06-04 EP EP10384002A patent/EP2392319A1/en not_active Withdrawn
-
2011
- 2011-06-03 PL PL11723885T patent/PL2575778T3/pl unknown
- 2011-06-03 RU RU2012157256/15A patent/RU2567843C2/ru active
- 2011-06-03 SG SG2012080545A patent/SG185385A1/en unknown
- 2011-06-03 SI SI201131160A patent/SI2575778T1/sl unknown
- 2011-06-03 AR ARP110101933A patent/AR081774A1/es not_active Application Discontinuation
- 2011-06-03 KR KR1020127033847A patent/KR101556700B1/ko active Active
- 2011-06-03 SM SM20170261T patent/SMT201700261T1/it unknown
- 2011-06-03 CA CA2798090A patent/CA2798090C/en active Active
- 2011-06-03 WO PCT/EP2011/002749 patent/WO2011151080A1/en not_active Ceased
- 2011-06-03 ES ES11723885.7T patent/ES2622192T3/es active Active
- 2011-06-03 DK DK11723885.7T patent/DK2575778T3/en active
- 2011-06-03 NZ NZ603457A patent/NZ603457A/en unknown
- 2011-06-03 BR BR112012030704A patent/BR112012030704A2/pt not_active Application Discontinuation
- 2011-06-03 HR HRP20170594TT patent/HRP20170594T1/hr unknown
- 2011-06-03 CN CN201180026578.9A patent/CN102946871B/zh active Active
- 2011-06-03 EP EP16203254.4A patent/EP3158994A1/en not_active Withdrawn
- 2011-06-03 MY MYPI2012004769A patent/MY156859A/en unknown
- 2011-06-03 TW TW100119536A patent/TWI508722B/zh active
- 2011-06-03 EP EP11723885.7A patent/EP2575778B1/en active Active
- 2011-06-03 PT PT117238857T patent/PT2575778T/pt unknown
- 2011-06-03 AU AU2011260608A patent/AU2011260608B2/en active Active
- 2011-06-03 UA UAA201300099A patent/UA109661C2/uk unknown
- 2011-06-03 US US13/701,192 patent/US8846744B2/en active Active
- 2011-06-03 RS RS20170378A patent/RS55878B1/sr unknown
- 2011-06-03 PH PH1/2012/502171A patent/PH12012502171A1/en unknown
- 2011-06-03 JP JP2013512793A patent/JP5800016B2/ja active Active
- 2011-06-03 LT LTEP11723885.7T patent/LT2575778T/lt unknown
- 2011-06-03 HU HUE11723885A patent/HUE033999T2/en unknown
- 2011-06-03 MX MX2012014087A patent/MX351507B/es active IP Right Grant
-
2012
- 2012-10-28 IL IL222731A patent/IL222731A/en active IP Right Grant
- 2012-10-29 TN TNP2012000515A patent/TN2012000515A1/en unknown
- 2012-11-21 ZA ZA2012/08767A patent/ZA201208767B/en unknown
- 2012-12-12 CO CO12224962A patent/CO6660469A2/es unknown
-
2013
- 2013-01-04 EC ECSP13012368 patent/ECSP13012368A/es unknown
-
2017
- 2017-04-07 CY CY20171100419T patent/CY1118813T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530952A5 (enExample) | ||
| RU2012157256A (ru) | Фармацевтические композиции сокристаллов трамадола и коксибов | |
| US11911509B2 (en) | Pharmaceutical composition comprising Lenvatinib mesylate | |
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| JP2015518885A5 (enExample) | ||
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| TWI774159B (zh) | 含有托格列淨（Tofogliflozin）之固體製劑及其製造方法 | |
| JP2015521191A5 (enExample) | ||
| EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
| RU2020110236A (ru) | Состав леналидомида с немедленным высвобождением | |
| WO2013006146A1 (en) | Effervescent formulations comprising dexketoprofen | |
| US20150025112A1 (en) | Orally disintegrating tablet formulations of donepezil | |
| WO2020262618A1 (en) | Meloxicam-containing granulated product | |
| US20200397700A1 (en) | Granular composition, production method for granular composition, and dissolution property improvement method for granular composition | |
| DK3166596T3 (en) | Pharmaceutical dosage forms | |
| JP2022140430A5 (enExample) | ||
| JPWO2021123192A5 (enExample) | ||
| WO2016012398A1 (en) | Zaltoprofen and muscle relaxant combinations | |
| WO2021020455A1 (ja) | ビルダグリプチン含有乾式造粒末、ビルダグリプチン含有錠剤及びその製造方法 | |
| JP2017014151A (ja) | 光安定性を向上した、シロドシンを含有する有核錠 | |
| JP7423297B2 (ja) | 口腔内崩壊錠およびその製造方法 | |
| EP2801352B1 (en) | Orally disintegrating formulations of Lacosamid | |
| JP7362302B2 (ja) | レベチラセタムを含有する錠剤とその製造方法 | |
| JP2018115130A (ja) | エルロチニブ塩酸塩含有医薬組成物の製造方法 | |
| JP6304751B2 (ja) | ワルファリン含有固形製剤及びその製造方法 |